Optimizing efficacy of mucosal vaccines

Ayman M Gebril, Manal Alsaadi, Reinaldo Acevedo, Alexander Mullen, Valerie Ferro

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

In general, there are only a few vaccines administered via mucosal routes, as the mucosal immune system presents numerous hurdles, including diversity in mucosal surface structure, complexity in immune cell interaction and limitations in experimental methodology. This therefore necessitates a range of strategies to be used for each target area. With reference to the three main routes of delivery and associated mucosal surfaces (oral/intestinal, nasal/respiratory and female genital tract), this review examines how coadministration of immune-stimulatory molecules, adjuvants, delivery systems and mucoadhesives are used to improve mucosal vaccine efficacy. Key considerations to the development of next-generation mucosal vaccines include improved efficacy and safety, technological advancements in medical devices to enable convenience and better administration, as well as reduced manufacturing costs.
LanguageEnglish
Pages1139-1155
Number of pages16
JournalExpert Review of Vaccines
Volume11
Issue number9
DOIs
Publication statusPublished - Sep 2012

Fingerprint

Vaccines
Nose
Cell Communication
Immune System
Safety
Costs and Cost Analysis
Equipment and Supplies

Keywords

  • mucosal vaccine
  • vaccines
  • mucosal vaccines
  • mucosal immune system
  • adjuvant
  • delivery systems
  • mucoadhesives

Cite this

Gebril, Ayman M ; Alsaadi, Manal ; Acevedo, Reinaldo ; Mullen, Alexander ; Ferro, Valerie. / Optimizing efficacy of mucosal vaccines. In: Expert Review of Vaccines. 2012 ; Vol. 11, No. 9. pp. 1139-1155.
@article{af082bfd7a814f6f9dc6ef98dcc460b5,
title = "Optimizing efficacy of mucosal vaccines",
abstract = "In general, there are only a few vaccines administered via mucosal routes, as the mucosal immune system presents numerous hurdles, including diversity in mucosal surface structure, complexity in immune cell interaction and limitations in experimental methodology. This therefore necessitates a range of strategies to be used for each target area. With reference to the three main routes of delivery and associated mucosal surfaces (oral/intestinal, nasal/respiratory and female genital tract), this review examines how coadministration of immune-stimulatory molecules, adjuvants, delivery systems and mucoadhesives are used to improve mucosal vaccine efficacy. Key considerations to the development of next-generation mucosal vaccines include improved efficacy and safety, technological advancements in medical devices to enable convenience and better administration, as well as reduced manufacturing costs.",
keywords = "mucosal vaccine, vaccines, mucosal vaccines , mucosal immune system , adjuvant, delivery systems, mucoadhesives",
author = "Gebril, {Ayman M} and Manal Alsaadi and Reinaldo Acevedo and Alexander Mullen and Valerie Ferro",
year = "2012",
month = "9",
doi = "10.1586/ERV.12.81",
language = "English",
volume = "11",
pages = "1139--1155",
journal = "Expert Review of Vaccines",
issn = "1476-0584",
number = "9",

}

Optimizing efficacy of mucosal vaccines. / Gebril, Ayman M; Alsaadi, Manal; Acevedo, Reinaldo; Mullen, Alexander; Ferro, Valerie.

In: Expert Review of Vaccines, Vol. 11, No. 9, 09.2012, p. 1139-1155.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Optimizing efficacy of mucosal vaccines

AU - Gebril, Ayman M

AU - Alsaadi, Manal

AU - Acevedo, Reinaldo

AU - Mullen, Alexander

AU - Ferro, Valerie

PY - 2012/9

Y1 - 2012/9

N2 - In general, there are only a few vaccines administered via mucosal routes, as the mucosal immune system presents numerous hurdles, including diversity in mucosal surface structure, complexity in immune cell interaction and limitations in experimental methodology. This therefore necessitates a range of strategies to be used for each target area. With reference to the three main routes of delivery and associated mucosal surfaces (oral/intestinal, nasal/respiratory and female genital tract), this review examines how coadministration of immune-stimulatory molecules, adjuvants, delivery systems and mucoadhesives are used to improve mucosal vaccine efficacy. Key considerations to the development of next-generation mucosal vaccines include improved efficacy and safety, technological advancements in medical devices to enable convenience and better administration, as well as reduced manufacturing costs.

AB - In general, there are only a few vaccines administered via mucosal routes, as the mucosal immune system presents numerous hurdles, including diversity in mucosal surface structure, complexity in immune cell interaction and limitations in experimental methodology. This therefore necessitates a range of strategies to be used for each target area. With reference to the three main routes of delivery and associated mucosal surfaces (oral/intestinal, nasal/respiratory and female genital tract), this review examines how coadministration of immune-stimulatory molecules, adjuvants, delivery systems and mucoadhesives are used to improve mucosal vaccine efficacy. Key considerations to the development of next-generation mucosal vaccines include improved efficacy and safety, technological advancements in medical devices to enable convenience and better administration, as well as reduced manufacturing costs.

KW - mucosal vaccine

KW - vaccines

KW - mucosal vaccines

KW - mucosal immune system

KW - adjuvant

KW - delivery systems

KW - mucoadhesives

UR - http://www.expert-reviews.com/loi/erv

U2 - 10.1586/ERV.12.81

DO - 10.1586/ERV.12.81

M3 - Article

VL - 11

SP - 1139

EP - 1155

JO - Expert Review of Vaccines

T2 - Expert Review of Vaccines

JF - Expert Review of Vaccines

SN - 1476-0584

IS - 9

ER -